Choice Institutional Equities has maintained a 'BUY' rating on Park Medi World Ltd, projecting a 20% upside with a target price of ₹350. The brokerage expects the healthcare company’s revenue to grow from ₹16.8 billion in fiscal year 2026 to ₹39.4 billion by fiscal year 2029, while maintaining stable EBITDA margins of 26.5%, according to livemint.com.
The positive outlook follows a management meeting and a visit to Park Medi World's facilities, where Choice Broking highlighted the company's aggressive capacity expansion plans. The brokerage's assessment reflects confidence in the hospital operator's growth strategy and operational efficiency, reinforcing its bullish stance on the stock, as reported by livemint.com.
Park Medi World’s forecasted growth aligns with the broader trend of India's healthcare sector emerging as a strong market performer. The expected revenue more than doubling over three years underscores the sector’s expansion potential. This recommendation comes amid a market environment where select hospital stocks continue to attract investor interest due to rising healthcare demand, per livemint.com.
Park Medi World’s stock performance and growth projections will be closely watched during its upcoming quarterly earnings announcements. The brokerage’s target price and revenue estimates provide a benchmark for investors assessing the company’s market position and financial health in the evolving healthcare landscape, according to livemint.com.